BIIB vs. MTD: Biogen vs. Mettler-Toledo Stock Comparison

November 11, 2026

How do Biogen (BIIB) and Mettler-Toledo (MTD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Biogen (BIIB) and Mettler-Toledo (MTD) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIIB is classified in Biotechnology while MTD is classified in Life Sciences Tools & Services.

Company profile comparison for Biogen (BIIB) and Mettler-Toledo (MTD)
Profile Item	BIIB	MTD
Name	Biogen Inc.	Mettler-Toledo International Inc.
Country/Region	United States	Switzerland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	36.71 billion USD	34.25 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	September 17, 1991	November 14, 1997
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BIIB

MTD

GSPC

Biogen (BIIB) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Biogen (BIIB) and Mettler-Toledo (MTD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Biogen (BIIB) and Mettler-Toledo (MTD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Biogen (BIIB) and Mettler-Toledo (MTD)
Metric	BIIB	MTD
Total Return (1Y)	65.44%	21.58%
Total Return (3Y, Annualized)	4.62%	19.54%
Total Return (5Y, Annualized)	-0.96%	2.36%

Risk Profile

Drawdown History

BIIB

MTD

GSPC

Biogen (BIIB) vs. Mettler-Toledo (MTD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Biogen (BIIB) and Mettler-Toledo (MTD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Biogen (BIIB) and Mettler-Toledo (MTD)
Metric	BIIB	MTD
Volatility (1Y, Annualized)	34.58%	31.70%
Beta (5Y)	0.08	1.15
Max Drawdown (5Y)	-64.35%	-43.47%
Avg. Volume (3M)	1.05M	197.80K

Risk-Adjusted Performance

Risk-Return Positioning

BIIB and MTD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Biogen (BIIB) and Mettler-Toledo (MTD)
Metric	BIIB	MTD
Sharpe Ratio (1Y)	1.77	0.55
Sortino Ratio (1Y)	2.77	0.75

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Biogen (BIIB) earns 1.87% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.87%

Max: 109.18%
Q3: 6.23%
BIIB: 1.87%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
MTD: --

Biogen (BIIB) vs. Mettler-Toledo (MTD): MTD does not report ROE, so it has no value marker; BIIB is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Mettler-Toledo (MTD) at 22.25% converts revenue to bottom-line profit above its industry’s benchmark range, while Biogen (BIIB) at 3.38% keeps roughly the typical share for its industry.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.38%

Max: 18.05%
Q3: 4.78%
BIIB: 3.38%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.25%

MTD: 22.25%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Biogen (BIIB) at 24.12% and Mettler-Toledo (MTD) at 28.70% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

24.12%

Max: 83.12%
BIIB: 24.12%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.70%

Max: 83.12%
MTD: 28.70%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Biogen (BIIB) and Mettler-Toledo (MTD)
Metric	BIIB	MTD
ROE (TTM)	1.87%	--
ROA (TTM)	4.94%	20.09%
Net Margin (TTM)	3.38%	22.25%
Operating Margin (TTM)	24.12%	28.70%
Gross Margin (TTM)	75.77%	59.16%

Growth

Revenue Growth

Both Biogen (BIIB) at 2.22% and Mettler-Toledo (MTD) at 3.98% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Biogen (BIIB) at -21.38% and Mettler-Toledo (MTD) at 3.88% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Biogen (BIIB) and Mettler-Toledo (MTD)
Metric	BIIB	MTD
Revenue Growth (YoY)	2.22%	3.98%
Revenue Growth (3Y CAGR)	-0.94%	0.90%
EPS Growth (YoY)	-21.38%	3.88%
EPS Growth (3Y CAGR)	-25.04%	3.06%

Financial Strength

Current Ratio (MRQ)

Both Biogen (BIIB) at 1.95 and Mettler-Toledo (MTD) at 1.10 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.95

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BIIB: 1.95
Min: 0.10

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.10

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
MTD: 1.10
Min: 0.10

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Biogen (BIIB) at 0.41 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.41

Max: 1.42
Q3: 0.65
BIIB: 0.41
Median: 0.15
Q1: 0.02
Min: 0.00

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.06

MTD: 26.06
Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Biogen (BIIB) and Mettler-Toledo (MTD)
Metric	BIIB	MTD
Current Ratio (MRQ)	1.95	1.10
Debt / Equity (MRQ)	0.41	26.06
Net Debt / EBITDA	1.97	1.58

Dividends

Dividend Yield (TTM)

Neither Biogen (BIIB) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Biogen (BIIB) nor Mettler-Toledo (MTD) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIIB: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

MTD: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Biogen (BIIB) and Mettler-Toledo (MTD)
Metric	BIIB	MTD
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Mettler-Toledo (MTD) at 37.38 is near its industry’s usual P/E ratio, while Biogen (BIIB) at 107.51 sits above its peer range — an unusually expensive price for BIIB’s trailing earnings.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.51

BIIB: 107.51
Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

37.38

Max: 85.34
Q3: 43.46
MTD: 37.38
Median: 26.69
Q1: 13.30
Min: 0.07

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Biogen (BIIB) at 3.57 and Mettler-Toledo (MTD) at 8.16 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.57

Max: 58.18
Q3: 25.77
Median: 7.30
BIIB: 3.57
Q1: 3.01
Min: 0.01

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max: 58.18
Q3: 25.77
MTD: 8.16
Median: 7.30
Q1: 3.01
Min: 0.01

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Biogen (BIIB) at 1.94 sits near its industry’s typical P/B ratio, while Mettler-Toledo (MTD) at 442.71 prices above its benchmark range — MTD looks rich relative to book.

BIIB

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94

Max: 13.53
Q3: 6.54
Median: 3.25
BIIB: 1.94
Q1: 1.69
Min: -5.59

MTD

Pharmaceuticals, Biotechnology & Life Sciences industry group

442.71

MTD: 442.71
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

Biogen (BIIB) vs. Mettler-Toledo (MTD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Biogen (BIIB) and Mettler-Toledo (MTD)
Metric	BIIB	MTD
P/E Ratio (TTM)	107.51	37.38
P/S Ratio (TTM)	3.57	8.16
P/B Ratio (MRQ)	1.94	442.71
Free Cash Flow Yield (TTM)	2.20%	1.97%